Hjem › Akut myelogen leukemi › Connecticut
Kliniske studier for Akut myelogen leukemi i Connecticut
17 studier for Akut myelogen leukemi søker deltakere på steder i Connecticut.
Byer i Connecticut
Offisiell studietekst (engelsk)
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
- Yale University, New Haven
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT06484062Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Yale University, New Haven
RekruttererFase 2
Alder 18 til 59 · Alle kjønn · Oppdatert 28. sep. 2026 · NCT05554393MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Yale University, New Haven
- Veterans Affairs Connecticut Healthcare System-West Haven Campus, West Haven
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT05564390Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Yale University, New Haven
- Veterans Affairs Connecticut Healthcare System-West Haven Campus, West Haven
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT06317649Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Yale University, New Haven
RekruttererFase 2
Alder 18 til 59 · Alle kjønn · Oppdatert 22. sep. 2026 · NCT05554406A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Connecticut Children's Medical Center, Hartford
- Yale University, New Haven
RekruttererFase 3
6 Months – 21 Years · Alle kjønn · Oppdatert 17. sep. 2026 · NCT04293562The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Connecticut Children's Medical Center, Hartford
- Yale University, New Haven
RekruttererFase 1/2
Opp til 22 år · Alle kjønn · Oppdatert 25. aug. 2026 · NCT04726241Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- Yale University, New Haven
RekruttererFase 3
29 Days – 21 Years · Alle kjønn · Oppdatert 24. aug. 2026 · NCT05183035Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- Hartford HealthCare Cancer Institute, Hartford
- Yale University School of Medicine, New Haven
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 20. aug. 2026 · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Smilow Cancer Hospital at Yale New Haven, New Haven
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 20. aug. 2026 · NCT06001788ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
- Yale University, Yale Cancer Center, New Haven
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 18. aug. 2026 · NCT06656494A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Yale New Haven Hospital, New Haven
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 6. jul. 2026 · NCT01351545BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
- Yale New Haven Hospital, New Haven
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 15. jun. 2026 · NCT05768932A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Yale University, New Haven
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 30. apr. 2026 · NCT04256317Revumenib in Combination With 7+3 + Midostaurin in AML
- Yale Cancer Center, New Haven
RekruttererFase 1
Alder 18 til 75 · Alle kjønn · Oppdatert 25. mar. 2026 · NCT06313437A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Yale Cancer Center and Smilow Cancer Hospital, New Haven
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 13. mar. 2026 · NCT05735184Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Yale University, New Haven
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 26. aug. 2025 · NCT03850574Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.